- Home
- RLAY vs SBFM Comparison
RLAY vs SBFM Comparison
Compare RLAY & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- SBFM
- Stock Information
- Founded
- RLAY 2015
- SBFM 2006
- Country
- RLAY United States
- SBFM United States
- Employees
- RLAY N/A
- SBFM N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- RLAY Health Care
- SBFM Health Care
- Exchange
- RLAY Nasdaq
- SBFM Nasdaq
- Market Cap
- RLAY N/A
- SBFM 4.9M
- IPO Year
- RLAY 2020
- SBFM N/A
- Fundamental
- Price
- RLAY $2.97
- SBFM $1.24
- Analyst Decision
- RLAY Strong Buy
- SBFM Strong Buy
- Analyst Count
- RLAY 11
- SBFM 1
- Target Price
- RLAY $18.40
- SBFM $15.00
- AVG Volume (30 Days)
- RLAY 2.6M
- SBFM 790.9K
- Earning Date
- RLAY 05-05-2025
- SBFM 05-19-2025
- Dividend Yield
- RLAY N/A
- SBFM N/A
- EPS Growth
- RLAY N/A
- SBFM N/A
- EPS
- RLAY N/A
- SBFM N/A
- Revenue
- RLAY $7,679,000.00
- SBFM $34,874,283.00
- Revenue This Year
- RLAY N/A
- SBFM $192.48
- Revenue Next Year
- RLAY $440.45
- SBFM N/A
- P/E Ratio
- RLAY N/A
- SBFM N/A
- Revenue Growth
- RLAY N/A
- SBFM 44.75
- 52 Week Low
- RLAY $1.78
- SBFM $1.17
- 52 Week High
- RLAY $10.72
- SBFM $23.20
- Technical
- Relative Strength Index (RSI)
- RLAY 52.88
- SBFM 37.73
- Support Level
- RLAY $2.71
- SBFM $1.24
- Resistance Level
- RLAY $3.48
- SBFM $1.45
- Average True Range (ATR)
- RLAY 0.27
- SBFM 0.12
- MACD
- RLAY 0.01
- SBFM 0.01
- Stochastic Oscillator
- RLAY 51.61
- SBFM 15.38
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.